DEB-TACE联合仑伐替尼对不可切除中晚期肝癌微环境和疗效影响

摘要/Abstract

摘要： 目的探讨载药微球肝动脉化疗栓塞(DEB-TACE)联合仑伐替尼治疗不可切除中晚期肝细胞癌(HCC)的疗效和安全性。方法选择海安市人民医院肿瘤科2021年1月—2022年3月收治的不可切除中晚期HCC患者70例,随机分为观察组和对照组;在口服仑伐替尼的基础上,观察组采用DEB-TACE治疗,对照组采用碘化油肝动脉化疗栓塞术(cTACE)治疗;观察治疗前后肿瘤内环境和肝生化指标的变化,以及疗效和安全性指标。结果观察组治疗后3个月的ORR、DCR和1年生存率分别为77.14%、91.43%和57.14%,高于对照组的54.29%、71.43%和37.14%;观察组的1年复发率为20.00%,低于对照组的42.86%,差异均有统计学意义(χ²=4.086, 3.695, 3.369, 4.879, 均P<0.05)。治疗3个月后,观察组的血清缺氧诱导因子-1α(HIF-α)、肿瘤特异性生长因子(TSGF)和肝细胞生长因子(HGF)水平为(308.47±32.65)pg/mL、(54.36±5.81)U/mL和(4.37±0.83) μg/L,低于对照组的(382.45±38.39) pg/mL、(63.49±6.34) U/mL和(5.08±0.96) μg/L,差异均有统计学意义(t=7.516, 8.342, 8.754, 均P<0.05);血清丙氨酸氨基转移酶(ALT)和总胆红素(TBil)为(58.83±6.73) U/L和(21.69±3.12) μmol/L,低于对照组的(72.56±7.45) U/L和(23.25±3.18)μmol/L,白蛋白(Alb)为(34.56±2.37)g/L,高于对照组的(32.89±2.29) g/L,差异均有统计学意义(t=5.163, 4.746, 3.725, 均P<0.05)。观察组的不良反应发生率略低于对照组,差异无统计学意义(P>0.05)。结论 DEB-TACE联合仑伐替尼治疗不可切除中晚期HCC,能改善肿瘤病灶内环境降,减轻肝损伤,提高临床治疗效果,安全性较高。

关键词: 肝细胞癌, 载药微球肝动脉化疗栓塞, 仑伐替尼, 肿瘤微环境, 安全性

Abstract: Objective To investigate the efficacy and safety of DEB-TACE combined with lenvatinib in the treatment of unresectable advanced hepatocellular carcinoma (HCC). Methods Seventy patients with unresectable advanced HCC admitted to the Department of Oncology, Haian People's Hospital from January 2021 to March 2022 were randomly divided into an observation group and a control group. On the basis of oral lenvatinib, the observation group was treated with DEB-TACE, and the control group was treated with iodized oil hepatic arterial chemoembolization (cTACE). The changes of tumor internal environment and liver function indexes, as well as the efficacy and safety indexes were observed before and after treatment. Results The 3-month objective response rate (ORR), disease control rate (DCR) and 1-year survival rate of the observation group were 77.14%, 91.43% and 57.14%, respectively, which were higher than those of 54.29%, 71.43% and 37.14% in the control group. The 1-year recurrence rate of the observation group was 20.00%, which was lower than that of the control group (42.86%), and the difference was statistically significant (χ²=4.086, 3.695, 3.369, 4.879, all P<0.05). After 3 months of treatment, the serum levels of hypoxia-inducible factor-1α (HIF-α), tumor-specific growth factor (TSGF) and hepatocyte growth factor (HGF) in the observation group were 308.47±32.65 pg/mL, 54.36±5.81 U/mL, and 4.37±0.83 μg/L, respectively. They were lower than those of 382.45±38.39 pg/mL, 63.49±6.34 U/mL, and 5.08±0.96 μg/L in the control group, and the differences were statistically significant (t=7.516, 8.342, 8.754, all P<0.05). The serum alanine aminotransferase (ALT) and total bilirubin (TBil) levels in the observation group were 58.83±6.73 U/L and 21.69±3.12 μmol/L, respectively, which were lower than those of 72.56±7.45 U/L and 23.25±3.18 μmol/L in the control group, whereas the albumin (Alb) level in the observation group was 34.56±2.37 g/L, which was higher than that of 32.89±2.29 g/L in the control group, and the differences were statistically significant (t=5.163, 4.746, 3.725, all P<0.05). The incidence of adverse reactions in the observation group was slightly lower than that in the control group, without statistical significance (P>0.05). Conclusion DEB-TACE combined with lenvatinib in the treatment of unresectable middle and advanced HCC can improve the internal environment of tumor lesions, reduce liver damage, and improve clinical treatment effect with high safety.

Key words: Hepatocellular Carcinoma, DEB-TACE, Tumor microenvironment, Lenvatinib, Security

江微, 张燕, 陆滢滢. DEB-TACE联合仑伐替尼对不可切除中晚期肝癌微环境和疗效影响[J]. 肝脏, 2024, 29(10): 1200-1204.

JIANG Wei, ZHANG Yan, LU Ying-ying. Effect of DEB-TACE combined with Lenvatinib in the treatment of unresectable middle and advanced liver cancer[J]. Chinese Hepatolgy, 2024, 29(10): 1200-1204.

/ 推荐

参考文献

[1] Rallis KS, Makrakis D, Ziogas IA, et al. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances[J]. World J Clin Oncol,2022,13(6):448-472.
[2] Shimose S, Iwamoto H, Tanaka M, et al. Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma[J]. Oncology,2020,98(8):558-565.
[3] Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges[J]. Nat Rev Clin Oncol,2018,15(5):325-340.
[4] Jia GR, Valkenburgh JV, Chen AZ, et al. Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol,2022,14(2):e1749.
[5] Wang TB, Chen B, Meng T, et al. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma[J]. Bioengineered,2021,12(1):1555-1575.
[6] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗规范(2022年版)[J]. 肿瘤防治研究,2022,49(3):251-276.
[7] Campani C, Capone Manuela, Liotta F, et al. Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma[J]. Dig Liver Dis,2022,54(7): 911-917.
[8] Ghanaati H, Mohammadifard M, Mohammadifard M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma[J]. J Family Med Prim Care,202110(10):3553-3560.
[9] Li X, He GW, Su F, et al. Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma[J]. Asian J Pharm Sci,2020,15(6):739-751.
[10] Meng FG, Li YY, Liu Q, et al. Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model[J]. Front Oncol,2022,10(12):e906971.
[11] 何海涛, 刘尚大, 韦广旭, 等. 对比DEB-TACE与cTACE治疗不可切除的肝内胆管细胞癌的有效性及安全性[J]. 肝脏,2022,27(12):1292-1295.
[12] 孙小虎, 王璐, 白静慧, 等. 晚期肝癌免疫微环境CD38表达水平与PD-1抑制剂疗效相关性分析[J]. 肝脏,2023,28(1):75-78.
[13] 朱明强, 丁佑铭. 肝癌微环境靶向与免疫治疗的研究现状[J]. 临床肝胆病杂志,2022,38(8):1913-1917.
[14] Bahcivanc iBasak, Shafiha R, Gkoutos GV. Associating transcriptomics data with inflammatory markers to understand tumour microenvironment in hepatocellular carcinoma[J]. Cancer Med,2023,12(1):696-711.
[15] Zakaria S, Nawaya R, Abdel-Hamid NM, et al. Targeting the HIF-1α/Cav-1 Pathway with a Chicory Extract/Daidzein Combination Plays a Potential Role in Retarding Hepatocellular Carcinoma[J]. Curr Cancer Drug Targets,2021,21(10):881-896.
[16] Tang L, Zhang XM. Serum TSGF and miR-214 levels in patients with hepatocellular carcinoma and their predictive value for the curative effect of transcatheter arterial chemoembolization[J]. Ann Palliat Med,2020,9(4):2111-2117.
[17] Christian S, Melanie L, Wang BC, et al. TLR3 promotes hepatocyte proliferation after partial hepatectomy by stimulating uPA expression and the release of tissue‐bound HGF MTTLR3[J]. The FASEB Journal,2020,34(8):10387-10397.
[18] Fan WZ, Zhu BW, Yue SF, et al. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis[J]. Cancer Med,2023,12(1):61-72.
[19] 王浩, 高海军, 伊正甲, 等. 载药微球化疗栓塞治疗在肝癌肝移植术前应用的现状与进展[J]. 国际生物医学工程杂志,2020,43(3):255-259.
[20] 徐仁良, 沈松柏, 余龙伍, 等. 载药微球经动脉化疗栓塞与传统肝动脉化疗栓塞分别联合索拉非尼治疗中晚期肝细胞肝癌的有效性和安全性对比[J]. 临床外科杂志,2023,31(4):383-386.
[21] 蒋成胜, 俞广进, 熊奇如. DEB-TACE与cTACE治疗不可切除肝细胞性肝癌的疗效与安全性对比:系统综述与荟萃分析[J]. 肝胆外科杂志,2020,28(1):17-21.
[22] Shao G, Wang J, Zhou X, et al. Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma[J]. Front Public Health, 2022,26(10):e963058.